Tiziano Barbui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8496580/publications.pdf

Version: 2024-02-01

146 papers	18,953 citations	22153 59 h-index	11939 134 g-index
146 all docs	146 docs citations	146 times ranked	7221 citing authors

#	Article	IF	Citations
1	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	27.0	1,543
2	Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. New England Journal of Medicine, 2004, 350, 114-124.	27.0	911
3	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
4	Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. New England Journal of Medicine, 1995, 332, 1132-1137.	27.0	787
5	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
6	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine, 2013, 368, 22-33.	27.0	664
7	Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. Journal of Clinical Oncology, 2005, 23, 2224-2232.	1.6	631
8	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	1.4	575
9	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€“essential thrombocythemia (IPSET-thrombosis). Blood, 2012, 120, 5128-5133.	1.4	461
10	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. Journal of Clinical Oncology, 2011, 29, 3179-3184.	1.6	441
11	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 2007, 110, 840-846.	1.4	419
12	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
13	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	6.2	404
14	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 2005, 105, 2664-2670.	1.4	389
15	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 2011, 117, 5857-5859.	1.4	376
16	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	1.6	373
17	Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 2007, 109, 2446-2452.	1.4	356
18	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	1.6	344

#	Article	IF	Citations
19	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
20	Myeloproliferative neoplasms and thrombosis. Blood, 2013, 122, 2176-2184.	1.4	303
21	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 2007, 109, 2310-2313.	1.4	295
22	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	1.4	286
23	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	1.4	233
24	A prognostic model to predict survival in 867 World Health Organizationâ€“defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 2012, 120, 1197-1201.	1.4	222
25	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	1.4	219
26	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	1.4	216
27	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	1.4	216
28	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 162-173.	4.1	213
29	Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Experimental Hematology, 2005, 33, 523-530.	0.4	212
30	Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2020, 95, 1599-1613.	4.1	204
31	Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2019, 94, 133-143.	4.1	177
32	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Experimental Hematology, 2007, 35, 702-711.	0.4	169
33	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. Journal of Clinical Oncology, 2008, 26, 2732-2736.	1.6	169
34	Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2017, 92, 94-108.	4.1	168
35	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	3.5	160
36	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144

#	Article	IF	Citations
37	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. Blood, 2009, 114, 759-763.	1.4	137
38	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
39	Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112, 4061-4068.	1.4	136
40	Masked polycythemia Vera (mPV): Results of an international study. American Journal of Hematology, 2014, 89, 52-54.	4.1	130
41	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 2019, 134, 1498-1509.	1.4	123
42	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	1.4	112
43	Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood, 2008, 111, 666-671.	1.4	106
44	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	4.1	105
45	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Advances, 2019, 3, 1729-1737.	5.2	105
46	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 2012, 119, 2239-2241.	1.4	90
47	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Experimental Hematology, 2009, 37, 1016-1021.	0.4	89
48	Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 2.	6.2	85
49	White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood, 2015, 126, 560-561.	1.4	82
50	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
51	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	1.4	79
52	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	4.6	79
53	Plateletâ€induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 2011, 86, 337-342.	4.1	78
54	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 2014, 89, 588-590.	4.1	75

#	Article	IF	Citations
55	Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 2003, 101, 3749-3749.	1.4	70
56	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	7.2	70
57	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia, 2019, 33, 1996-2005.	7.2	67
58	Polycythemia vera treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 3.	6.2	65
59	Masked polycythemia vera diagnosed according to WHO and BCSH classification. American Journal of Hematology, 2014, 89, 199-202.	4.1	64
60	Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Reviews, 2008, 22, 235-245.	5.7	60
61	A reappraisal of the benefitâ€risk profile of hydroxyurea in polycythemia vera: A propensityâ€matched study. American Journal of Hematology, 2017, 92, 1131-1136.	4.1	57
62	Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia, 2021, 35, 3339-3351.	7.2	57
63	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 2010, 116, 1051-1055.	1.4	56
64	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
65	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer Journal, 2018, 8, 112.	6.2	55
66	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	4.1	53
67	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	1.4	52
68	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2010, 104, 151-156.	3.4	51
69	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. American Journal of Hematology, 2014, 89, 306-309.	4.1	50
70	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€defined early/prefibrotic myelofibrosis: An international study of 264 patients. American Journal of Hematology, 2012, 87, 669-672.	4.1	49
71	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2010, 85, 97-100.	4.1	48
72	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	2.5	47

#	Article	IF	Citations
73	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
74	Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 64.	6.2	47
75	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 2021, 11, 199.	6.2	47
76	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
77	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. American Journal of Hematology, 2017, 92, E5-E6.	4.1	45
78	Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Advances, 2020, 4, 380-386.	5.2	45
79	A randomized phase 3 trial of interferon-Î± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 139, 2931-2941.	1.4	45
80	Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 65.	6.2	44
81	Myeloproliferative Disease in Pregnancy and Other Management Issues. Hematology American Society of Hematology Education Program, 2006, 2006, 246-252.	2.5	42
82	Cerebral vein thrombosis in patients with <scp>P</scp>hiladelphiaâ€negative myeloproliferative neoplasms An <scp>E</scp>uropean <scp>L</scp>eukemia <scp>N</scp>et study. American Journal of Hematology, 2014, 89, E200-5.	4.1	42
83	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
84	Myeloproliferative neoplasms: Morphology and clinical practice. American Journal of Hematology, 2016, 91, 430-433.	4.1	39
85	Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. Mayo Clinic Proceedings, 2015, 90, 1283-1293.	3.0	38
86	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 21.	6.2	35
87	Second cancers in MPN: Survival analysis from an international study. American Journal of Hematology, 2020, 95, 295-301.	4.1	34
88	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia, 2021, 35, 2989-2993.	7.2	34
89	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	5.2	34
90	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	4.1	33

#	Article	IF	Citations
91	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica, 2019, 104, 2391-2399.	3.5	33
92	Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 104.	6.2	32
93	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	1.4	32
94	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31
95	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. American Journal of Hematology, 2018, 93, 698-703.	4.1	31
96	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer Journal, 2022, 12, 28.	6.2	31
97	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	7.2	30
98	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	4.1	29
99	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.8	28
100	Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thrombosis Research, 2016, 140, S71-S75.	1.7	28
101	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. American Journal of Hematology, 2017, 92, 417-419.	4.1	26
102	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	6.2	26
103	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer Journal, 2021, 11, 21.	6.2	26
104	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	6.2	25
105	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica, 2017, 102, e219-e221.	3.5	21
106	Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12657.	2.3	21
107	The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leukemia and Lymphoma, 2017, 58, 1481-1487.	1.3	20
108	Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. Blood Cancer Journal, 2018, 8, 5.	6.2	20

#	Article	IF	Citations
109	Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer Journal, 2018, 8, 124.	6.2	20
110	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHOâ€criteria and stratified by calendar period of diagnosis. American Journal of Hematology, 2015, 90, 434-437.	4.1	19
111	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 100.	6.2	19
112	The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer Journal, 2020, 10, 22.	6.2	19
113	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood, 2020, 135, 381-386.	1.4	18
114	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	4.1	18
115	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	4.6	17
116	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
117	Evidence-based management of polycythemia vera. Best Practice and Research in Clinical Haematology, 2006, 19, 483-493.	1.7	15
118	ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood, 2017, 129, 1226-1227.	1.4	14
119	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
120	Cerebral venous thrombosis and myeloproliferative neoplasms: A threeâ€center study of 74 consecutive cases. American Journal of Hematology, 2021, 96, 1580-1586.	4.1	13
121	Extreme thrombocytosis in lowâ€risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American Journal of Hematology, 2021, 96, E182-E184.	4.1	11
122	Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer Journal, 2021, 11, 115.	6.2	9
123	Refining prognostication of thrombosis in <scp>ET</scp>. American Journal of Hematology, 2016, 91, 361-363.	4.1	8
124	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	4.1	8
125	Feasibility of Randomised Clinical Trials in Rare Diseases: The Case of Polycythemia Vera. Leukemia and Lymphoma, 1996, 22, 121-127.	1.3	7
126	From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?. Leukemia, 2020, 34, 2837-2839.	7.2	7

#	Article	IF	Citations
127	Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms. European Journal of Haematology, 2021, 106, 250-259.	2.2	7
128	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	7.2	7
129	Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Psychophysiology, 2003, 2, 248-56.	1.1	7
130	An agenda for future research projects in polycythemia vera and essential thrombocythemia. Haematologica, 2020, 105, 1999-2003.	3.5	6
131	Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study). European Journal of Internal Medicine, 2020, 72, 60-66.	2.2	5
132	Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic. Current Hematologic Malignancy Reports, 2021, 16, 455-463.	2.3	5
133	Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?. Blood Advances, 2019, 3, 3951-3952.	5.2	4
134	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). Blood, 2014, 124, 1849-1849.	1.4	4
135	A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis. Blood, 2021, 138, 237-237.	1.4	4
136	1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Advances, 2022, 6, 3835-3839.	5.2	4
137	Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 103.	6.2	3
138	Comments on preâ€fibrotic myelofibrosis and how should it be managed. British Journal of Haematology, 2019, 186, 358-360.	2.5	3
139	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	7.2	2
140	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
141	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. Blood, 2019, 134, 4170-4170.	1.4	2
142	Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study. Blood, 2020, 136, 47-48.	1.4	2
143	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Leukemia, 2020, 34, 1208-1209.	7.2	1
144	Response to: Ruxolitinib withdrawal due to the COVID-19. Leukemia, 2021, 35, 1219-1219.	7.2	1

#	Article	IF	Citations
145	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. Blood, 2021, 138, 1499-1499.	1.4	1
146	Finding the needle by modeling the haystack: Pulmonary embolism in an emergency patient with cardiorespiratory manifestations. Expert Systems With Applications, 2022, 189, 116066.	7.6	0